arrow
S

Sergio Fernandéz-Pello

cabueñes university hospital
H指数:22
被引数:5,258

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Urine Glycosaminoglycan Scores for Surveillance of Recurrence in Intermediate- and High-risk Nonmetastatic Clear Cell Renal Cell Carcinoma—An Observational Prospective Multicentre Diagnostic Test Cohort Study

尿糖胺聚糖评分用于监测中高危非转移性透明细胞肾细胞癌复发—一项前瞻性多中心诊断试验队列研究

2025-08-270
OAAI
Hospital Volume as a Determinant of Outcomes After Partial Nephrectomy: A Systematic Review by the European Association of Urology Renal Cell Carcinoma Guidelines Panel

医院手术量作为部分肾切除术预后的决定因素:欧洲泌尿外科学会肾细胞癌指南专家组系统评价

2025-06-010
PRE
European Association of Urology-American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 Update
2023-06-0159
OA
A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines Panel
2023-03-010
PRE
European Association of Urology Guidelines Panel on Renal Cell Carcinoma Update on the New World Health Organization Classification of Kidney Tumours 2022: The Urologist?s Point of View
2023-02-0114
PRE
The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma

2022更新的欧洲泌尿外科协会肾细胞癌辅助免疫检查点抑制剂治疗指南

2023-01-0132
OA
A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines Panel
2023-01-016
OA
2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma

2021更新欧洲泌尿外科协会关于使用辅助帕博利珠单抗治疗肾细胞癌的指南

2022-02-0127
PRE
The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care
2021-10-01115
PREAI
The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium

组织学亚型对肾细胞癌患者术后复发的发生率,时间和模式的影响-RECUR Consortium的结果

2021-06-0138
PREAI
Should patients with low-risk renal cell carcinoma be followed differently after nephron-sparing surgery vs radical nephrectomy?

低危肾细胞癌患者在保留肾单位手术和根治性肾切除术后是否应该有不同的随访?

2021-04-266
OAAI
Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naive Metastatic Clear-Cell Renal Cell Carcinoma
2021-03-01101
PREAI
Limitations of Available Studies Prevent Reliable Comparison Between Tumour Ablation and Partial Nephrectomy for Patients with Localised Renal Masses: A Systematic Review from the European Association of Urology Renal Cell Cancer Guideline Panel

现有研究的局限性阻碍了肿瘤消融和肾部分切除术对局部肾脏肿块患者的可靠比较: 来自欧洲泌尿外科协会肾细胞癌指南小组的系统评价

2020-08-0152
PREAI
Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel
2020-02-0173
OAAI
Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis

最初定位的透明细胞肾细胞癌的长期随访结果: RECUR数据库分析

2019-09-0173
OAAI
Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
2019-08-01175
OAAI
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update

欧洲泌尿外科协会肾细胞癌指南: 2019更新

2019-05-011.1K
OAAI